The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
Open accessPublished version of a preprint
Abstract
Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without compromising the validity of conclusions and it is essential to distinguish pre-planned from unplanned changes that may also occur. The reporting of ADs in randomised trials is inconsistent and needs improving. Incompletely reported AD randomised trials are difficult to reproduce and are hard to interpret and synthesise. This consequently hampers their ability to inform practice as well as future research and contributes to research waste. Better transparency and adequate reporting will enable the potential benefits of ADs to be realised. This extension to the Consolidated Standards Of Reporting Trials (CONSORT) 2010 statement was developed to enhance the reporting of randomised AD clinical trials. We developed an Adaptive designs CONSORT Extension (ACE) guideline through a two-stage Delphi process with input from multidisciplinary key stakeholders in clinical trials research in the public and private sectors from 21 countries, followed by a consensus meeting. Members of the CONSORT Group were involved during the development process. The paper presents the ACE checklists for AD randomised trial reports and abstracts, as well as an explanation with examples to aid the application of the guideline. The ACE checklist comprises seven new items, nine modified items, six unchanged items for which additional explanatory text clarifies further considerations for ADs, and 20 unchanged items not requiring further explanatory text. The ACE abstract checklist has one new item, one modified item, one unchanged item with additional explanatory text for ADs, and 15 unchanged items not requiring further explanatory text. The intention is to enhance transparency and improve reporting of AD randomised trials to improve the interpretability of their results and reproducibility of their methods, results and inference. We also hope indirectly to facilitate the much-needed knowledge transfer of innovative trial designs to maximise their potential benefits. In order to encourage its wide dissemination this article is freely accessible on the BMJ and Trials journal websites. “To maximise the benefit to society, you need to not just do research but do it well” Douglas G Altman
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Extensions to CONSORT have been developed to address methodological issues in reporting different types of trial designs, data, and interventions.
“Extensions to CONSORT have been developed to tackle the methodological issues associated with reporting different types of trial designs, data, and interventions.”
From CONSORT 2025 statement: Updated guideline for reporting randomised trials (2025) · cites this paper as [33]
The Purpose of the paper section says CONSORT extensions have been developed for reporting particular trial designs, hypotheses, and interventions. This supports the general point, but the cited passage names hypotheses rather than the claim’s different types of data. (LLM, conf=0.88)
Experimental — accuracy not yet measuredExtensions to CONSORT have been developed to tackle the methodological issues associated with reporting different types of trial designs, data, and interventions.
“Extensions to CONSORT have been developed to tackle the methodological issues associated with reporting different types of trial designs, data, and interventions.”
From CONSORT 2025 statement: updated guideline for reporting randomised trials (2025) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371 · see citing works
Self-citationMoher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883 · see citing works
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957 · see citing works
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
Nogueira, R. G., Jadhav, A. P., Haussen, D. C., Bonafé, A., Budzik, R. F., Bhuva, P., Yavagal, D. R., Ribó, M., Cognard, C., Hanel, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706442 · Cited by 5,667 · see citing works
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824 · see citing works
Self-citationConsort 2010 statement: extension to cluster randomised trials
Campbell, M. K., Piaggio, G., Elbourne, D. R., Altman, D. G., & for the CONSORT Group (2012) · BMJ · doi:10.1136/bmj.e5661 · Cited by 3,510 · see citing works
Self-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311 · see citing works
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428 · see citing works
Self-citationAn improved Bonferroni procedure for multiple tests of significance
SIMES, R. J. (1986) · Biometrika · doi:10.1093/biomet/73.3.751 · Cited by 2,396 · see citing works
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,983 · see citing works
Self-citationGroup sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831 · see citing works
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593 · see citing works
Self-citationSystematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003081 · Cited by 1,546 · see citing works
Self-citation(2002) · The Lancet · doi:10.1016/s0140-6736(02)08651-8 · Cited by 1,459 · see citing works
Guidance for Developers of Health Research Reporting Guidelines
Moher, D., Schulz, K. F., Simera, I., & Altman, D. G. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000217 · Cited by 1,437 · see citing works
Self-citationOn closed testing procedures with special reference to ordered analysis of variance
Marcus, R., Peritz, E., & Gabriel, K. R. (1976) · Biometrika · doi:10.1093/biomet/63.3.655 · Cited by 1,417 · see citing works
Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer
Kelsen, D. P., Ginsberg, R., Pajak, T. F., Sheahan, D. G., Gunderson, L., Mortimer, J., Estes, N., Haller, D. G., Ajani, J., Kocha, W., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812313392704 · Cited by 1,343 · see citing works
Group Sequential Methods with Applications to Clinical Trials
Jennison, C., & Turnbull, B. W. (1999) · Chapman & Hall/CRC eBooks · doi:10.1201/9780367805326 · Cited by 1,339 · see citing works
Moher, D., Jones, A., Lepage, L., & for the CONSORT Group (2001) · JAMA · doi:10.1001/jama.285.15.1992 · Cited by 1,027 · see citing works
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A. S., Stewart, D. J., Hicks, M. E., Erasmus, J. J., Gupta, S. K., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 888 · see citing works
Plint, A. C., Moher, D., Morrison, A., Schulz, K., Altman, D. G., Hill, C., & Gaboury, I. (2006) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00557.x · Cited by 872 · see citing works
Self-citationEvaluation of Experiments with Adaptive Interim Analyses
Bauer, P., & Kohne, K. (1994) · Biometrics · doi:10.2307/2533441 · Cited by 869 · see citing works
Adaptive designs in clinical trials: why use them, and how to run and report them
Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1017-7 · Cited by 829 · cited 10× · see citing works
“Notably, classification of ADs in the literature is inconsistent [13, 22], while the scope and complexity of trial adaptations and underpinning statistical methods continues to broaden [18, 20, 106].”
BackgroundInfluentialSelf-citationA Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma
Léauté-Labrèze, C., Hoeger, P. H., Mazereeuw‐Hautier, J., Guibaud, L., Baselga, E., Pošiūnas, G., Phillips, R., Cáceres, H., López‐Gutiérrez, J. C., Ballona, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1404710 · Cited by 794 · see citing works
CONSORT 2010 statement: extension to randomised crossover trials
Dwan, K., Li, T., Altman, D. G., & Elbourne, D. (2019) · BMJ · doi:10.1136/bmj.l4378 · Cited by 785 · see citing works
Self-citationI-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C. C., Gj, K., Hylton, N., Berry, D., & Esserman, L. J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 767 · see citing works
Hopewell, S., Clarke, M., Moher, D., Wager, E., Middleton, P., Altman, D. G., Schulz, K. F., & and the CONSORT Group (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050020 · Cited by 674 · see citing works
Self-citationThe Design and Analysis of Sequential Clinical Trials.
Harrington, D. T., & Whitehead, J. (1985) · Journal of the American Statistical Association · doi:10.2307/2288093 · Cited by 637 · see citing works
Bassler, D. (2010) · JAMA · doi:10.1001/jama.2010.310 · Cited by 613 · see citing works
Adaptive Sample Size Calculations in Group Sequential Trials
Lehmacher, W., & Wassmer, G. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.01286.x · Cited by 599 · see citing works
Avery, K. N. L., Williamson, P. R., Gamble, C., O'Connell Francischetto, E., Metcalfe, C., Davidson, P., Williams, H., & Blazeby, J. M. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013537 · Cited by 575 · see citing works
Modification of Sample Size in Group Sequential Clinical Trials
Cui, L., Hung, H. M. J., & Wang, S. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00853.x · Cited by 574 · see citing works
Statistical Principles for Clinical Trials
Kay, R. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600201 · Cited by 573 · see citing works
Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease
Thadhani, R., Appelbaum, E. A., Pritchett, Y., Chang, Y., Wenger, J., Tamez, H. E., Bhan, I., Agarwal, R., Zoccali, C., Wanner, C., et al. (2012) · JAMA · doi:10.1001/jama.2012.120 · Cited by 567 · see citing works
Biomarkers and surrogate endpoints in clinical trials
Fleming, T. R., & Powers, J. H. (2012) · Statistics in Medicine · doi:10.1002/sim.5403 · Cited by 546 · see citing works
Designed Extension of Studies Based on Conditional Power
Proschan, M. A., & Hunsberger, S. (1995) · Biometrics · doi:10.2307/2533262 · Cited by 536 · see citing works
Self-citationGuidelines for the Content of Statistical Analysis Plans in Clinical Trials
Gamble, C., Krishan, A., Stocken, D., Lewis, S., Juszczak, E., Doré, C., Williamson, P. R., Altman, D. G., Montgomery, A., Lim, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.18556 · Cited by 536 · see citing works
Self-citationThe Design and Analysis of Sequential Clinical Trials.
Whitehead, J. (1997) · Biometrics · doi:10.2307/2533535 · Cited by 524 · see citing works
Testing for baseline balance in clinical trials
Senn, S. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131703 · Cited by 503 · see citing works
Adaptive design methods in clinical trials–a review
Chow, S.-C., & Chang, M. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-11 · Cited by 482 · cited 4× · see citing works
“This may include deviations from pre-planned adaptations and decision rules [15, 66], as well as changes to timing and frequency of interim analyses.”
BackgroundInfluentialCONSORT for reporting randomised trials in journal and conference abstracts
Hopewell, S., Clarke, M., Moher, D., Wager, E., Middleton, P., Altman, D. G., & Schulz, K. F. (2008) · The Lancet · doi:10.1016/s0140-6736(07)61835-2 · Cited by 458 · see citing works
Self-citationBerry, S. M., Connor, J. T., & Lewis, R. J. (2015) · JAMA · doi:10.1001/jama.2015.2316 · Cited by 379 · see citing works
de Boer, M. R., Waterlander, W. E., Kuijper, L. D., Steenhuis, I. H., & Twisk, J. W. (2015) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/s12966-015-0162-z · Cited by 370 · see citing works
Adaptive increase in sample size when interim results are promising: a practical guide with examples
Mehta, C. R., & Pocock, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4102 · Cited by 367 · see citing works
Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease: Indacaterol Versus Tiotropium
Donohue, J. F., Fogarty, C. M., Lötvall, J. O., Mahler, D. A., Worth, H., Yorgancıoğlu, A., Iqbal, A., Swales, J., Owen, R. J., Higgins, M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200910-1500oc · Cited by 357 · see citing works
Stochastically curtailed tests in long–term clinical trials
Lan, K. K. G., Simon, R. M., & Halperin, M. (1982) · Sequential Analysis · doi:10.1080/07474948208836014 · Cited by 356 · see citing works
The Theory of Response‐Adaptive Randomization in Clinical Trials
Hu, F., & Rosenberger, W. F. (2006) · Wiley series in probability and statistics · doi:10.1002/047005588x · Cited by 352 · see citing works
Comparability of Randomised Groups
Altman, D. G. (1985) · Journal of the Royal Statistical Society Series D (The Statistician) · doi:10.2307/2987510 · Cited by 329 · see citing works
Self-citationEfficiencies of platform clinical trials: A vision of the future
Saville, B. R., & Berry, S. M. (2016) · Clinical Trials · doi:10.1177/1740774515626362 · Cited by 326 · see citing works
Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement
Juszczak, E., Altman, D. G., Hopewell, S., & Schulz, K. (2019) · JAMA · doi:10.1001/jama.2019.3087 · Cited by 324 · see citing works
Self-citationAdaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group
Gallo, P. P., Chuang‐Stein, C., Dragalin, V., Gaydos, B. L., Krams, M., & Pinheiro, J. C. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600614742 · Cited by 323 · see citing works
Monitoring clinical trials: Conditional or predictive power?
Spiegelhalter, D. J., Freedman, L. S., & Blackburn, P. R. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90003-6 · Cited by 317 · see citing works
Combining different phases in the development of medical treatments within a single trial
Bauer, P., & Kieser, M. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990730)18:14 · Cited by 289 · see citing works
Stahl, M., Walz, M. K., Riera‐Knorrenschild, J., Stuschke, M., Sandermann, A., Bitzer, M., Wilke, H., & Budach, W. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.04.027 · Cited by 284 · see citing works
MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial
Zajicek, J., Hobart, J. C., Slade, A. L., Barnes, D., & Mattison, P. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302468 · Cited by 277 · see citing works
Bretz, F., Schmidli, H., König, F., Racine, A., & Maurer, W. (2006) · Biometrical Journal · doi:10.1002/bimj.200510232 · Cited by 273 · see citing works
Adaptive designs for confirmatory clinical trials
Bretz, F., König, F., Brannath, W., Glimm, E., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3538 · Cited by 265 · see citing works
Adaptive trial designs: a review of barriers and opportunities
Kairalla, J. A., Coffey, C. S., Thomann, M. A., & Muller, K. E. (2012) · Trials · doi:10.1186/1745-6215-13-145 · Cited by 249 · see citing works
Group sequential designs using a family of type I error probability spending functions
Hwang, I. K., Shih, W. J., & de Cani, J. S. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091207 · Cited by 247 · see citing works
Testing and estimation in flexible group sequential designs with adaptive treatment selection
Posch, M., König, F., Branson, M., Brannath, W., Dunger‐Baldauf, C., & Bauer, P. (2005) · Statistics in Medicine · doi:10.1002/sim.2389 · Cited by 244 · cited 6× · see citing works
“Using the methods of Posch and Bauer [64], as agreed upon during the special protocol assessment process, a p-value was obtained for comparison of each dose to the placebo arm from the stage I data, and an additional p-value was obtained for comparison of the optimal dose to the placebo arm from the independent data g…”
MethodInfluentialSample size re-estimation without unblinding for normally distributed outcomes with unknown variance
Gould, A. L., & Shih, W. J. (1992) · Communication in Statistics- Theory and Methods · doi:10.1080/03610929208830947 · Cited by 241 · see citing works
COMPare: a prospective cohort study correcting and monitoring 58 misreported trials in real time
Goldacre, B., Drysdale, H., Dale, A., Milosevic, I., Slade, E., Hartley, P., Marston, C., Powell-Smith, A., Heneghan, C., & Mahtani, K. R. (2019) · Trials · doi:10.1186/s13063-019-3173-2 · Cited by 233 · see citing works
Twenty‐five years of confirmatory adaptive designs: opportunities and pitfalls
Bauer, P., Bretz, F., Dragalin, V., König, F., & Wassmer, G. (2015) · Statistics in Medicine · doi:10.1002/sim.6472 · Cited by 231 · see citing works
A review of methods for futility stopping based on conditional power
Lachin, J. M. (2005) · Statistics in Medicine · doi:10.1002/sim.2151 · Cited by 228 · see citing works
Parameter Estimation Following Group Sequential Hypothesis Testing
Emerson, S. S., & Fleming, T. R. (1990) · Biometrika · doi:10.1093/biomet/77.4.875 · Cited by 225 · see citing works
Jenkins, M. A., Stone, A. M., & Jennison, C. (2010) · Pharmaceutical Statistics · doi:10.1002/pst.472 · Cited by 214 · see citing works
Jennison, C., & Turnbull, B. W. (1999) · Chapman & Hall/CRC machine learning & pattern recognition/Chapman & Hall/CRC machine learning & pattern recognition series · doi:10.1201/9781584888581 · Cited by 212 · see citing works
Sample Size Recalculation in Internal Pilot Study Designs: A Review
Friede, T., & Kieser, M. (2006) · Biometrical Journal · doi:10.1002/bimj.200510238 · Cited by 205 · see citing works
The Theory of Response-Adaptive Randomization in Clinical Trials
Hu, F., & Rosenberger, W. F. (2006) · Cited by 201 · see citing works
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology
Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P. P., Posch, M., & Racine-Poon, A. (2009) · Statistics in Medicine · doi:10.1002/sim.3559 · Cited by 200 · see citing works
Tröger, W., Galun, D. A., Reif, M., Schumann, A., Stanković, N., & Milicevic, M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.043 · Cited by 199 · see citing works
Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov
Bothwell, L. E., Avorn, J., Khan, N. F., & Kesselheim, A. S. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018320 · Cited by 198 · cited 1× · see citing works
“In summary, ADs are used in a relatively low proportion of trials, although their use is steadily increasing in both the public and private sectors [114 – 116], and they are frequently considered at the design stage [27].”
BackgroundCook, J. A., Julious, S. A., Sones, W., Hampson, L. V., Hewitt, C., Berlin, J. A., Ashby, D., Emsley, R., Fergusson, D. A., Walters, S. J., et al. (2018) · Trials · doi:10.1186/s13063-018-2884-0 · Cited by 197 · cited 1× · see citing works
“Criteria for claiming overall evidence (such as based on the probability of the treatment effect being above a certain value, targeted treatment effect of interest, and threshold for statistical significance [174, 175]); 4.”
Self-citationAdaptive assignment versus balanced randomization in clinical trials: A decision analysis
Berry, D. A., & Eick, S. G. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140302 · Cited by 196 · see citing works
Ivers, N. M., Taljaard, M., Dixon, S., Bennett, C., McRae, A., Taleban, J., Skea, Z., Brehaut, J. C., Boruch, R. F., Eccles, M. P., et al. (2011) · BMJ · doi:10.1136/bmj.d5886 · Cited by 193 · see citing works
Brannath, W., Burger, H. U., Glimm, E., Stallard, N., Vandemeulebroecke, M., & Wassmer, G. (2010) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2010.514453 · Cited by 193 · see citing works
Statistical Monitoring of Clinical Trials: a Unified Approach
Chernick, M. R. (2007) · Technometrics · doi:10.1198/tech.2007.s479 · Cited by 190 · see citing works
Adaptive Designs for Randomized Trials in Public Health
Brown, C. H., Ten Have, T. R., Jo, B., Dagne, G., Wyman, P. A., Muthén, B., & Gibbons, R. D. (2009) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.031308.100223 · Cited by 184 · see citing works
Key design considerations for adaptive clinical trials: a primer for clinicians
Thorlund, K., Haggstrom, J., Park, J. J., & Mills, E. J. (2018) · BMJ · doi:10.1136/bmj.k698 · Cited by 182 · see citing works
Sydes, M. R., Parmar, M., Mason, M. D., Clarke, N. W., Amos, C. L., Anderson, J., Bono, J. S. D., Dearnaley, D. P., Dwyer, J., Green, C., et al. (2012) · Trials · doi:10.1186/1745-6215-13-168 · Cited by 173 · see citing works
Self-citationAdaptive Modifications of Hypotheses After an Interim Analysis
Hommel, G. (2001) · Biometrical Journal · doi:10.1002/1521-4036(200109)43:5 · Cited by 170 · see citing works
A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection
Magirr, D., Jaki, T., & Whitehead, J. (2012) · Biometrika · doi:10.1093/biomet/ass002 · Cited by 162 · see citing works
Self-citationPractical problems in interim analyses, with particular regard to estimation
Pocock, S., & Hughes, M. D. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90059-7 · Cited by 160 · see citing works
Design of Experiments: Ranking and Selection
Santner, T. J., & Tamhane, A. C. (1984) · Cited by 157 · see citing works
Adaptive Two Stage Designs and the Conditional Error Function
Posch, M., & Bauer, P. (1999) · Biometrical Journal · doi:10.1002/(sici)1521-4036(199910)41:6 · Cited by 153 · see citing works
Avoidable waste of research related to inadequate methods in clinical trials
Yordanov, Y., Dechartres, A., Porcher, R., Boutron, I., Altman, D. G., & Ravaud, P. (2015) · BMJ · doi:10.1136/bmj.h809 · Cited by 153 · see citing works
Self-citationHeatley, G. J., Sood, P., Goldstein, D. J., Uriel, N. Y., Cleveland, J. C., Middlebrook, D., & Mehra, M. R. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.021 · Cited by 151 · see citing works
Estimands in clinical trials – broadening the perspective
Akacha, M., Bretz, F., & Ruberg, S. J. (2016) · Statistics in Medicine · doi:10.1002/sim.7033 · Cited by 151 · see citing works
Cook, J. A., Julious, S. A., Sones, W., Hampson, L. V., Hewitt, C., Berlin, J. A., Ashby, D., Emsley, R., Fergusson, D. A., Walters, S. J., et al. (2018) · BMJ · doi:10.1136/bmj.k3750 · Cited by 148 · see citing works
Self-citationSpeeding up the Evaluation of New Agents in Cancer
Parmar, M., Barthel, F. M.-S., Sydes, M. R., Langley, R. E., Kaplan, R. S., Eisenhauer, E. A., Brady, M. F., James, N. D., Bookman, M. A., Swart, A. M., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn267 · Cited by 143 · cited 1× · see citing works
“Evaluating multiple treatments in one trial allowing for early selection of promising treatments or dropping futile or unsafe treatments [53 – 55].”
BackgroundSelf-citationPredictive Probability Early Termination Plans For Phase II Clinical Trials
Herson, J. (1979) · Biometrics · doi:10.2307/2530109 · Cited by 143 · see citing works
Adaptive Designs: Terminology and Classification
Dragalin, V. (2006) · Drug Information Journal · doi:10.1177/216847900604000408 · Cited by 142 · see citing works
Statistical Consideration of Adaptive Methods in Clinical Development
Chow, S., Chang, M., & Pong, A. (2005) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-200062277 · Cited by 136 · see citing works
Wason, J. M. S., & Trippa, L. (2014) · Statistics in Medicine · doi:10.1002/sim.6086 · Cited by 136 · see citing works
Self-citationJin, Y., Sanger, N., Shams, I., Luo, C., Shahid, H., Li, G., Bhatt, M., Zielinski, L., Bantoto, B., Wang, M., et al. (2018) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s155103 · Cited by 134 · see citing works
Adaptive Dunnett tests for treatment selection
König, F., Brannath, W., Bretz, F., & Posch, M. (2007) · Statistics in Medicine · doi:10.1002/sim.3048 · Cited by 130 · see citing works
Stopping rules and estimation problems in clinical trials
Hughes, M. D., & Pocock, S. (1988) · Statistics in Medicine · doi:10.1002/sim.4780071204 · Cited by 128 · see citing works
Optimal design of multi‐arm multi‐stage trials
Wason, J. M. S., & Jaki, T. (2012) · Statistics in Medicine · doi:10.1002/sim.5513 · Cited by 127 · see citing works
Self-citationBiomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Antoniou, M., Jorgensen, A., & Kolamunnage‐Dona, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149803 · Cited by 125 · see citing works
James, N. D., Sydes, M. R., Mason, M. D., Clarke, N. W., Anderson, J., Dearnaley, D. P., Dwyer, J., Jovic, G., Ritchie, A. W., Russell, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70088-8 · Cited by 123 · see citing works
Ondra, T., Dmitrienko, A. A., Friede, T., Graf, A. C., Miller, F., Stallard, N., & Posch, M. (2015) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2015.1092034 · Cited by 122 · see citing works
Barrington, P., Chien, J. Y., Showalter, H. D. H., Schneck, K., Cui, S., Tibaldi, F., Ellis, B., & Hardy, T. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01364.x · Cited by 120 · see citing works
Estimating a treatment effect in survival studies in which patients switch treatment
Branson, M., & Whitehead, J. (2002) · Statistics in Medicine · doi:10.1002/sim.1219 · Cited by 120 · see citing works
Evaluation of Intravenous Peramivir for Treatment of Influenza in Hospitalized Patients
de Jong, M. D., Ison, M. G., Monto, A. S., Metev, H., Clark, C. L., O’Neil, B. J., Elder, J., McCullough, A. J., Collis, P., & Sheridan, W. P. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu632 · Cited by 118 · see citing works
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design
Barnes, P. J., Pocock, S., MAGNUSSEN, H., Iqbal, A., Krämer, B., Higgins, M., & Lawrence, D. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.01.003 · Cited by 116 · see citing works
Self-citationGood Practices for Adaptive Clinical Trials in Pharmaceutical Product Development
Gaydos, B. L., Anderson, K. M., Berry, D. A., Burnham, N., Chuang‐Stein, C., Dudinak, J., Fardipour, P., Gallo, P. P., Givens, S., Lewis, R. J., et al. (2009) · Drug Information Journal · doi:10.1177/009286150904300503 · Cited by 113 · see citing works
Some recommendations for multi-arm multi-stage trials
Wason, J. M. S., Magirr, D., Law, M. W.-M., & Jaki, T. (2012) · Statistical Methods in Medical Research · doi:10.1177/0962280212465498 · Cited by 113 · see citing works
Self-citationThe reassessment of trial perspectives from interim data—a critical view
Bauer, P., & König, F. (2005) · Statistics in Medicine · doi:10.1002/sim.2180 · Cited by 110 · see citing works
PLANNING AND REVISING THE SAMPLE SIZE FOR A TRIAL
Gould, A. L. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140922 · Cited by 108 · see citing works
The Design and Analysis of Sequential Clinical Trials (2nd ed.).
Lachenbruch, P. A., & Whitehead, J. (1993) · Journal of the American Statistical Association · doi:10.2307/2290372 · Cited by 108 · see citing works
Fernandes, R. M. F., van der Lee, J. H., & Offringa, M. (2009) · BMC Pediatrics · doi:10.1186/1471-2431-9-77 · Cited by 107 · cited 1× · see citing works
“However, these methods are rarely used or reported and the implications are unclear [45, 209, 235].”
Sample Size Reestimation: A Review and Recommendations
Chuang‐Stein, C., Anderson, K. M., Gallo, P. P., & Collins, S. H. (2006) · Drug Information Journal · doi:10.1177/216847900604000413 · Cited by 107 · see citing works
Adaptive designs undertaken in clinical research: a review of registered clinical trials
Hatfield, I., Allison, A., Flight, L., Julious, S. A., & Dimairo, M. (2016) · Trials · doi:10.1186/s13063-016-1273-9 · Cited by 107 · see citing works
Self-citationGroup Sequential Tests for Delayed Responses (with discussion)
Hampson, L. V., & Jennison, C. (2012) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/j.1467-9868.2012.01030.x · Cited by 104 · see citing works
Khalil, E. A. G., Weldegebreal, T., Younis, B. M., Omollo, R., Musa, A. M., Hailu, W., Abuzaid, A. A., Dorlo, T. P. C., Hurissa, Z., Yifru, S., et al. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002613 · Cited by 101 · see citing works
Critical concepts in adaptive clinical trials
Park, J., Thorlund, K., & Mills, E. J. (2018) · Clinical Epidemiology · doi:10.2147/clep.s156708 · Cited by 100 · see citing works
A comparison of methods for adaptive sample size adjustment
Friede, T., & Kieser, M. (2001) · Statistics in Medicine · doi:10.1002/sim.972 · Cited by 99 · see citing works
Selection and bias—Two hostile brothers
Bauer, P., König, F., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3716 · Cited by 99 · see citing works
Giles, F. J., Kantarjian, H. M., Cortes, J. E., Garcia‐Manero, G., Verstovšek, S., Faderl, S. H., Thomas, D. A., Ferrajoli, A., O'Brien, S. M., Wathen, J. K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.016 · Cited by 99 · see citing works
Elsäßer, A., Regnström, J., Vetter, T., König, F., Hemmings, R. J., Greco, M., Papaluca‐Amati, M., & Posch, M. (2014) · Trials · doi:10.1186/1745-6215-15-383 · Cited by 96 · see citing works
Flexible Sample Size Considerations Using Information-Based Interim Monitoring
Mehta, C. R., & Tsiatis, A. A. (2001) · Drug Information Journal · doi:10.1177/009286150103500407 · Cited by 94 · cited 6× · see citing works
“Bayesian GSD with futility early stopping; frequency and timing of interim analyses; adaptation decision-making criteria; criteria for claiming treatment benefit “ We adopted a group-sequential Bayesian design [182] with three stages, of 40 patients each (in total), and two interim analyses after 40 and 80 randomised…”
MethodInfluentialOverrunning and underrunning in sequential clinical trials
Whitehead, J. (1992) · Controlled Clinical Trials · doi:10.1016/0197-2456(92)90017-t · Cited by 92 · see citing works
Parmar, M., Sydes, M. R., Cafferty, F. H., Choodari‐Oskooei, B., Langley, R. E., Brown, L. C., Phillips, P. P. J., Spears, M. R., Rowley, S., Kaplan, R. S., et al. (2017) · Clinical Trials · doi:10.1177/1740774517725697 · Cited by 91 · see citing works
Self-citationWhen and How Can Endpoints Be Changed after Initiation of a Randomized Clinical Trial
Evans, S. R. (2007) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0020018 · Cited by 90 · see citing works
Continuous Infusion of Clonidine in Ventilated Newborns and Infants
Hünseler, C., Balling, G., Röhlig, C., Blickheuser, R., Trieschmann, U., Lieser, U., Dohna‐Schwake, C., Gebauer, C. M., Möller, O., Hering, F., et al. (2014) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000151 · Cited by 90 · see citing works
Benefits, challenges and obstacles of adaptive clinical trial designs
Chow, S., & Corey, R. G. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-79 · Cited by 88 · see citing works
Monitoring Clinical Trials Based on Predictive Probability of Significance
Choi, S. C., & Pepple, P. A. (1989) · Biometrics · doi:10.2307/2532056 · Cited by 88 · see citing works
Frequentist evaluation of group sequential clinical trial designs
Emerson, S. S., Kittelson, J. M., & Gillen, D. L. (2007) · Statistics in Medicine · doi:10.1002/sim.2901 · Cited by 87 · see citing works
Implementing Adaptive Designs: Logistical and Operational Considerations
Quinlan, J., & Krams, M. (2006) · Drug Information Journal · doi:10.1177/216847900604000409 · Cited by 84 · see citing works
No solution yet for combining two independent studies in the presence of heterogeneity
Gonnermann, A., Framke, T., Großhennig, A., & Koch, A. (2015) · Statistics in Medicine · doi:10.1002/sim.6473 · Cited by 83 · see citing works
Estimation in flexible two stage designs
Brannath, W., König, F., & Bauer, P. (2005) · Statistics in Medicine · doi:10.1002/sim.2258 · Cited by 83 · see citing works
Clinical trial designs incorporating predictive biomarkers
Renfro, L. A., Mallick, H., An, M., Sargent, D. J., & Mandrekar, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.008 · Cited by 83 · see citing works
Supplementary Analysis at the Conclusion of a Sequential Clinical Trial
Whitehead, J. (1986) · Biometrics · doi:10.2307/2531197 · Cited by 80 · see citing works
Mehta, C. R., Liu, L., & Theuer, C. P. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy464 · Cited by 78 · see citing works
Estimands and Their Role in Clinical Trials
Akacha, M., Bretz, F., Ohlssen, D. I., Rosenkranz, G., & Schmidli, H. (2017) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2017.1302358 · Cited by 77 · see citing works
Stopping clinical trials early for benefit: impact on estimation
Freidlin, B., & Korn, E. L. (2009) · Clinical Trials · doi:10.1177/1740774509102310 · Cited by 76 · see citing works
Coffey, C. S., & Kairalla, J. A. (2008) · Drugs in R&D · doi:10.2165/00126839-200809040-00003 · Cited by 75 · see citing works
A Bayesian adaptive design for clinical trials in rare diseases
Williamson, S. F., Jacko, P., Villar, S. S., & Jaki, T. (2016) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2016.09.006 · Cited by 74 · see citing works
Self-citationSkrivanek, Z., Gaydos, B. L., Chien, J. Y., Geiger, M. J., Heathman, M. A., Berry, S. M., Anderson, J. H., Forst, T. M., Miličević, Z., & Berry, D. A. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12305 · Cited by 73 · see citing works
Coffey, C. S., Levin, B. L., Clark, C., Timmerman, C., Wittes, J. T., Gilbert, P. R., & Harris, S. (2012) · Clinical Trials · doi:10.1177/1740774512461859 · Cited by 73 · see citing works
Steg, P. G. (2013) · JAMA · doi:10.1001/jama.2013.277165 · Cited by 73 · see citing works
A practical guide to Bayesian group sequential designs
Gsponer, T., Gerber, F., Bornkamp, B., Ohlssen, D. I., Vandemeulebroecke, M., & Schmidli, H. (2013) · Pharmaceutical Statistics · doi:10.1002/pst.1593 · Cited by 72 · see citing works
Maintaining confidentiality of interim data to enhance trial integrity and credibility
Fleming, T. R., SHARPLES, K. J., McCall, J. L., Moore, A., Rodgers, A., & Stewart, R. (2008) · Clinical Trials · doi:10.1177/1740774508089459 · Cited by 71 · see citing works
Quinlan, J., Gaydos, B. L., Maca, J., & Krams, M. (2010) · Clinical Trials · doi:10.1177/1740774510361542 · Cited by 70 · see citing works
Challenging Issues in Clinical Trial Design
Pocock, S., Clayton, T. C., & Stone, G. W. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.051 · Cited by 68 · see citing works
MiRoR network, Blanco, D., Biggane, A. M., & Cobo, E. (2018) · Trials · doi:10.1186/s13063-018-2475-0 · Cited by 68 · see citing works
Adaptive Design: Results of 2012 Survey on Perception and Use
Morgan, C. C., Huyck, S. B., Jenkins, M. A., Chen, L., Bedding, A. W., Coffey, C. S., Gaydos, B. L., & Wathen, J. K. (2014) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479014522468 · Cited by 67 · cited 1× · see citing works
“methods [29, 78, 107] and interest in their application by researchers and research funders [26, 28, 108].”
BackgroundAdaptive sample size modification in clinical trials: start small then ask for more?
Jennison, C., & Turnbull, B. W. (2015) · Statistics in Medicine · doi:10.1002/sim.6575 · Cited by 63 · see citing works
Chataway, J., Nicholas, R. S., Todd, S., Miller, D. H., Parsons, N., Valdés‐Márquez, E., Stallard, N., & Friede, T. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510382129 · Cited by 63 · see citing works
Self-citationConfidentiality and Trial Integrity Issues for Adaptive Designs
Gallo, P. P. (2006) · Drug Information Journal · doi:10.1177/216847900604000410 · Cited by 62 · see citing works
Sample size recalculation for binary data in internal pilot study designs
Friede, T., & Kieser, M. (2004) · Pharmaceutical Statistics · doi:10.1002/pst.140 · Cited by 62 · see citing works
Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock
Jones, A. E., Puskarich, M. A., Shapiro, N. I., Guirgis, F. W., Runyon, M. S., Adams, J. Y., Sherwin, R. L., Arnold, R., Roberts, B. W., Kurz, M. C., et al. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6076 · Cited by 61 · see citing works
The pragmatic clinical trial in a learning health care system
Lewis, R. (2016) · Clinical Trials · doi:10.1177/1740774516655097 · Cited by 60 · see citing works
The advantages and disadvantages of adaptive designs for clinical trials
Bauer, P., & Brannath, W. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03023-5 · Cited by 59 · see citing works
An overview of the design and conduct of the BATTLE trials.
Liu, S., & Lee, J. J. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.06.07 · Cited by 58 · see citing works
Stevely, A. K., Dimairo, M., Todd, S., Julious, S. A., Nicholl, J. P., Hind, D., & Cooper, C. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141104 · Cited by 58 · see citing works
Self-citationA seamless Phase IIB/III adaptive outcome trial: Design rationale and implementation challenges
Chen, Y. H. J., Gesser, R., & Luxembourg, A. T. (2014) · Clinical Trials · doi:10.1177/1740774514552110 · Cited by 56 · cited 1× · see citing works
“Investigating multiple research objectives that are traditionally examined in distinct trial phases, in one trial under a single protocol [74 – 76].”
A multi-stage drop-the-losers design for multi-arm clinical trials
Wason, J. M. S., Stallard, N., Bowden, J., & Jennison, C. (2014) · Statistical Methods in Medical Research · doi:10.1177/0962280214550759 · Cited by 56 · see citing works
Self-citationBayesian clinical trial designs
Jansen, J. O., Pallmann, P., MacLennan, G., & Campbell, M. (2017) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001638 · Cited by 56 · see citing works
Self-citationMistry, P., Dunn, J., & Marshall, A. (2017) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0393-6 · Cited by 56 · see citing works
Janackovic, K., & Puljak, L. (2018) · Trials · doi:10.1186/s13063-018-2976-x · Cited by 56 · see citing works
When is a seamless study desirable? Case studies from different pharmaceutical sponsors
Cuffe, R. L., Lawrence, D., Stone, A. M., & Vandemeulebroecke, M. (2014) · Pharmaceutical Statistics · doi:10.1002/pst.1622 · Cited by 55 · see citing works
Self-citationDwan, K., Kirkham, J. J., Williamson, P. R., & Gamble, C. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002709 · Cited by 55 · see citing works
Dimairo, M., Coates, E. J., Pallmann, P., Todd, S., Julious, S. A., Jaki, T., Wason, J. M. S., Mander, A., Weir, C. J., König, F., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1196-2 · Cited by 55 · see citing works
Self-citationApplication of Adaptive Designs – a Review
Bauer, P., & Einfalt, J. (2006) · Biometrical Journal · doi:10.1002/bimj.200510204 · Cited by 54 · see citing works
Optimal multistage designs for randomised clinical trials with continuous outcomes
Wason, J. M. S., Mander, A., & Thompson, S. G. (2011) · Statistics in Medicine · doi:10.1002/sim.4421 · Cited by 53 · cited 1× · see citing works
“These may encompass the maximum sample size, expected sample sizes under certain scenarios, probabilities of identifying beneficial treatments if they exist, and probabilities of making false positive claims of evidence [172, 173].”
BackgroundSelf-citationMacArthur, R. D., Hawkins, T., Brown, S. J., LaMarca, A., Clay, P. G., Barrett, A. C., Bortey, E. B., Paterson, C. A., Golden, P. L., & Forbes, W. P. (2013) · HIV Clinical Trials · doi:10.1310/hct1406-261 · Cited by 53 · see citing works
Alternative Views On Setting Clinical Trial Futility Criteria
Gallo, P. P., Mao, L., & Shih, V. H. (2014) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2014.932285 · Cited by 53 · see citing works
Design and Monitoring of Multi-Arm Multi-Stage Clinical Trials
Ghosh, P., Liu, L., Senchaudhuri, P., Gao, P., & Mehta, C. R. (2017) · Biometrics · doi:10.1111/biom.12687 · Cited by 53 · see citing works
Dimairo, M., Boote, J. D., Julious, S. A., Nicholl, J. P., & Todd, S. (2015) · Trials · doi:10.1186/s13063-015-0958-9 · Cited by 52 · see citing works
Self-citationBenefit–risk assessment: the use of clinical utility index
Ouellet, D. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740330903499265 · Cited by 51 · see citing works
Flexible sequential designs for multi‐arm clinical trials
Magirr, D., Stallard, N., & Jaki, T. (2014) · Statistics in Medicine · doi:10.1002/sim.6183 · Cited by 50 · see citing works
Self-citationCBER’s Experience With Adaptive Design Clinical Trials
Lin, M. J., Lee, S., Zhen, B., Scott, J., Horne, A. D., Solomon, G., & Russek‐Cohen, E. (2015) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479015604181 · Cited by 50 · see citing works
Self-citationOutcome reporting bias in randomized-controlled trials investigating antipsychotic drugs
Lancee, M., Lemmens, C. M. C., Kahn, R. S., Vinkers, C. H., & Luykx, J. J. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.203 · Cited by 50 · see citing works
Adaptive Design in Clinical Research: Issues, Opportunities, and Recommendations
Chang, M., Chow, S., & Pong, A. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600609718 · Cited by 49 · see citing works
Wang, H., Rosner, G. L., & Goodman, S. N. (2016) · Clinical Trials · doi:10.1177/1740774516649595 · Cited by 49 · see citing works
Vitamin D Receptor Activation and Left Ventricular Hypertrophy in Advanced Kidney Disease
Thadhani, R., Appelbaum, E. A., Chang, Y., Pritchett, Y., Bhan, I., Agarwal, R., Zoccali, C., Wanner, C., Lloyd‐Jones, D. M., Cannata-Andía, J. B., et al. (2011) · American Journal of Nephrology · doi:10.1159/000323551 · Cited by 48 · see citing works
Exact Confidence Bounds Following Adaptive Group Sequential Tests
Brannath, W., Mehta, C. R., & Posch, M. (2008) · Biometrics · doi:10.1111/j.1541-0420.2008.01101.x · Cited by 48 · see citing works
Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice
Cohen, D. R., Todd, S., Gregory, W. M., & Brown, J. M. (2015) · Trials · doi:10.1186/s13063-015-0697-y · Cited by 48 · see citing works
Self-citationLorch, U., O’Kane, M., & Täubel, J. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-84 · Cited by 47 · see citing works
Collignon, O., König, F., Koch, A., Hemmings, R. J., Pétavy, F., Saint-Raymond, A., Papaluca‐Amati, M., & Posch, M. (2018) · Trials · doi:10.1186/s13063-018-3012-x · Cited by 47 · see citing works
Self-citationOn Stopping a Randomized Clinical Trial for Futility
Herson, J., Buyse, M. E., & Wittes, J. T. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0140-7_5 · Cited by 46 · see citing works
Whitehead, J., & Jaki, T. (2008) · Statistics in Medicine · doi:10.1002/sim.3508 · Cited by 46 · cited 1× · see citing works
“The critical values for recommending that a treatment is taken to further testing at the interim and final analyses (2.782 and 2.086) have been chosen to guarantee these properties using a method described by Magirr et al. [177], generalising the approach of Whitehead and Jaki [178].”
MethodInfluentialSelf-citationA Bayesian adaptive design for biomarker trials with linked treatments
Wason, J. M. S., Abraham, J., Baird, R. D., Gournaris, I., Vallier, A.-L., Brenton, J. D., Earl, H. M., & Mander, A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.278 · Cited by 45 · cited 1× · see citing works
“…drop-the-loser with SSR [99]; inferentially seamless phase 2/3 AD with hypotheses selection [77] or population enrichment [100]; biomarker-stratified with RAR [101]; adaptive platform trials where arms can be added or stopped early [19, 24, 102]. reporting can help address these concerns [22, 27].”
BackgroundSelf-citationStatistical inference for cancer trials with treatment switching
Shao, J., Chang, M., & Chow, S. (2005) · Statistics in Medicine · doi:10.1002/sim.2128 · Cited by 45 · see citing works
Repeated confidence intervals for adaptive group sequential trials
Mehta, C. R., Bauer, P., Posch, M., & Brannath, W. (2007) · Statistics in Medicine · doi:10.1002/sim.3062 · Cited by 45 · see citing works
Wang, S.-J., & Hung, H. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.09.008 · Cited by 45 · see citing works
Exact inference for adaptive group sequential designs
Gao, P., Liu, L., & Mehta, C. R. (2013) · Statistics in Medicine · doi:10.1002/sim.5847 · Cited by 44 · see citing works
On the Independence of Data Monitoring Committee in Adaptive Design Clinical Trials
Chow, S., Corey, R., & Lin, M. J. (2012) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2012.676536 · Cited by 44 · see citing works
Multi-arm clinical trials with treatment selection: what can be gained and at what price?
Jaki, T. (2015) · Clinical Investigation · doi:10.4155/cli.15.13 · Cited by 43 · see citing works
Self-citationLewis, R. J., Angus, D. C., Laterre, P., Kjølbye, A. L., van der Meulen, E., Blemings, A., Graves, T., Russell, J. A., Carlsen, J. E., Jacobsen, K., et al. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201708-669sd · Cited by 43 · see citing works
Statistical testing for baseline differences between randomised groups is not meaningful
Harvey, L. A. (2018) · Spinal Cord · doi:10.1038/s41393-018-0203-y · Cited by 43 · see citing works
Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group
Phillips, A. J., Keene, O. N., & on behalf of the PSI Adaptive Design Expert Group (2006) · Pharmaceutical Statistics · doi:10.1002/pst.206 · Cited by 42 · see citing works
Self-citationWalter, S. D., Guyatt, G. H., Bassler, D., Briel, M., Ramsay, T., & Han, H. (2019) · Statistics in Medicine · doi:10.1002/sim.8142 · Cited by 41 · see citing works
Confirmatory Clinical Trials with an Adaptive Design
Koch, A. (2006) · Biometrical Journal · doi:10.1002/bimj.200510239 · Cited by 40 · see citing works
Geiger, M. J., Skrivanek, Z., Gaydos, B. L., Chien, J. Y., Berry, S. M., Berry, D. A., & Anderson, J. H. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600610 · Cited by 40 · see citing works
Bačkonja, M., Williams, L. J., Miao, X., Katz, N. P., & Chen, C. (2017) · Pain · doi:10.1097/j.pain.0000000000000983 · Cited by 40 · see citing works
Meurer, W. J., Legocki, L. J., Mawocha, S., Frederiksen, S. M., Guetterman, T. C., Barsan, W. G., Lewis, R. J., Berry, D. A., & Fetters, M. D. (2016) · Trials · doi:10.1186/s13063-016-1493-z · Cited by 39 · see citing works
Self-citationWason, J. M. S., & Mander, A. (2012) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2010.528104 · Cited by 37 · see citing works
Self-citation
Flagged first, then by citations
2 of the 278 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
CONSORT 2025 statement: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081123 · Cited by 1,195 · see citing works
Self-citationCONSORT 2025 statement: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00672-5 · Cited by 510 · see citing works
Self-citationHopewell, S., Chan, A., Collins, P. G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · JAMA · doi:10.1001/jama.2025.4347 · Cited by 430 · see citing works
Self-citationCONSORT 2025 statement: updated guideline for reporting randomized trials
Hopewell, S., Chan, A., Collins, P. G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03635-5 · Cited by 321 · see citing works
“Examples of extensions for trial designs include recommendations for adaptive designs 33 , cluster trials 34 , crossover trials 35 , early phase trials 36 , factorial trials 37 , non-inferiority and equivalence trials 38 , pragmatic trials 39 , multi-arm trials 40 , n-of-1 trials 41 , pilot and…”
Self-citationLuchini, C., Veronese, N., Nottegar, A., Shin, J. I., Gentile, G., Granziol, U., Soysal, P., Alexinschi, O., Smith, L., & Solmi, M. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.2068 · Cited by 240 · see citing works
“transparency and improving the report of adaptive-design randomized trials, to increase both the interpretability of their results and reproducibility of their methods, results, and inference.(25)”
MethodReis, G., Silva, E. A. D. S. M., Silva, D. C. M., Thabane, L., Singh, G., Park, J., Forrest, J. I., Harari, O., dos Santos, C. V. Q., Almeida, A. P. F. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6468 · Cited by 135 · see citing works
“9) Age, y Median (IQR) 53 (18-81) 54 (18-94) 53 (18-80) 53 (18-94) >50 127 (59.”
BackgroundInfluentialCONSORT 2025 statement: Updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · PLOS Medicine · doi:10.1371/journal.pmed.1004587 · Cited by 139 · see citing works
“Examples of extensions for trial designs include recommendations for adaptive designs [33], cluster trials [34], crossover trials [35], early phase trials [36], factorial trials [37], non-inferiority and equivalence trials [38], pragmatic trials [39], multi-arm trials [40], n-of-1 trials [41],…”
Self-citationTarantini, G., Mojoli, M., Varbella, F., Caporale, R., Rigattieri, S., Andò, G., Cirillo, P. L., Pierini, S., Santarelli, A., Sganzerla, P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.053 · Cited by 112 · see citing works
Burnett, T. D., Mozgunov, P., Pallmann, P., Villar, S. S., Wheeler, G., & Jaki, T. (2020) · BMC Medicine · doi:10.1186/s12916-020-01808-2 · Cited by 101 · see citing works
“Additionally, new reporting guidance for adaptive designs [200] has recently been published to facilitate uptake further.”
BackgroundSelf-citationHow to Use and Interpret the Results of a Platform Trial
Park, J., Detry, M. A., Murthy, S., Guyatt, G. H., & Mills, E. J. (2022) · JAMA · doi:10.1001/jama.2021.22507 · Cited by 86 · see citing works
Point estimation for adaptive trial designs I: A methodological review
Robertson, D. S., Choodari‐Oskooei, B., Dimairo, M., Flight, L., Pallmann, P., & Jaki, T. (2022) · Statistics in Medicine · doi:10.1002/sim.9605 · Cited by 56 · see citing works
Self-citationMiles, L. F., Burt, C. C., Arrowsmith, J. E., McKie, M. A., Villar, S. S., Govender, P., Shaylor, R., Tan, Z., Silva, R. D., & Falter, F. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003658 · Cited by 37 · see citing works
“(PDF) S1 Checklist.”
MethodInfluentialLee, K. M., Brown, L. C., Jaki, T., Stallard, N., & Wason, J. M. S. (2021) · Trials · doi:10.1186/s13063-021-05150-7 · Cited by 33 · see citing works
Self-citationPoint estimation for adaptive trial designs II : Practical considerations and guidance
Robertson, D. S., Choodari‐Oskooei, B., Dimairo, M., Flight, L., Pallmann, P., & Jaki, T. (2023) · Statistics in Medicine · doi:10.1002/sim.9734 · Cited by 28 · see citing works
“As highlighted by Dimairo et al.(2,3), the goal of clinical trials should be to provide reliable estimates of the treatment effect to inform accurate decision-making, but this can be compromised when an adaptive design is analysed with inappropriate statistical methods.”
BackgroundSelf-citationPerspectives on the application of CONSORT guidelines to randomised controlled trials in nutrition
Rigutto‐Farebrother, J., Ahles, S., Cade, J. E., Murphy, K. J., Plat, J., Schwingshackl, L., Roche, H. M., Shyam, S., Lachat, C. K., Minihane, A. M., et al. (2023) · European Journal of Nutrition · doi:10.1007/s00394-023-03137-5 · Cited by 28 · see citing works
Grayling, M. J., Bigirumurame, T., Cherlin, S., Ouma, L. O., Zheng, H., & Wason, J. M. S. (2021) · BMC Rheumatology · doi:10.1186/s41927-021-00192-5 · Cited by 25 · see citing works
“An adaptive design is one “that offers pre-planned opportunities to use accumulating trial data to modify aspects of an ongoing trial while preserving the validity and integrity of that trial” [17].”
Self-citationRandomised controlled trials in pre-hospital trauma: a systematic mapping review
Björklund, M. K., Cruickshank, M., Lendrum, R. A., & Gillies, K. (2021) · Scandinavian Journal of Trauma Resuscitation and Emergency Medicine · doi:10.1186/s13049-021-00880-8 · Cited by 18 · see citing works
“As such, attention to the recent adaptive design CONSORT extension will be key for those designing adaptive trials in this context to ensure adequate reporting [52].”
BackgroundEarwaker, M., Villar, S. S., Fox-Rushby, J. A., Duckworth, M., Dawson, S. N., Steele, J., Chiu, Y., Litton, E., Kunst, G., Murphy, G. J., et al. (2022) · Trials · doi:10.1186/s13063-022-06180-5 · Cited by 13 · see citing works
Solovyeva, O., Dimairo, M., Weir, C. J., Hee, S. W., Espinasse, A., Ursino, M., Patel, D., Kightley, A., Hughes, S., Jaki, T., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02937-0 · Cited by 13 · see citing works
Self-citationNine-month, all-oral regimens for rifampin-resistant tuberculosisPreprint
Guglielmetti, L., Khan, U. A., Velásquez, G. E., Gouillou, M., Abubakirov, A., Baudin, E., Berikova, E. A., Berry, C., Bonnet, M., Cellamare, M., et al. (2024) · medRxiv · doi:10.1101/2024.01.29.24301679 · Cited by 13 · see citing works
Xi, M., Dragsted, L. O., Tullin, M., Ernst, M., Zaharudin, N., & Barbera, G. L. (2020) · Metabolites · doi:10.3390/metabo11010011 · Cited by 10 · see citing works
“The contents reported throughout the paper were addressed according to each item demonstrated in both the CONSORT 2010 statement and Adaptive designs CONSORT Extension (ACE) statement [23,24].”
MethodGötte, H., Kirchner, M., Krisam, J., Allignol, A., Lamy, F.-X., Schüler, A., & Kieser, M. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2190 · Cited by 10 · see citing works
Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age?
Branch‐Elliman, W., Lehmann, L. S., Boden, W. E., Ferguson, R. E., & Monach, P. A. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100614 · Cited by 10 · see citing works
Renz, B. W., Adrion, C., Klinger, C., Ilmer, M., D’Haese, J. G., Buhr, H.-J., Mansmann, U., Werner, J., & PyloResPres study group (2021) · BMJ Open · doi:10.1136/bmjopen-2021-056191 · Cited by 10 · see citing works
White, D. A., Pye, C., Ridsdale, K., Dimairo, M., Mooney, C., Wright, J. T., Young, T. A., Cheong, Y. C., Drakeley, A., Mathur, R., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-076434 · Cited by 8 · see citing works
“22 For progression of OHSS severity, a mixed effects logistic regression model adjusted for stratification factors (site as a random effect and OHSS severity as a fixed effect) will be used and an adjusted difference in hospital-isation rates will be obtained using the delta method via margins.”
MethodSelf-citationResponse adaptive randomisation in clinical trials: Current practice, gaps and future directions
Wilson, I., Julious, S. A., Yap, C., Todd, S., & Dimairo, M. (2025) · Statistical Methods in Medical Research · doi:10.1177/09622802251348183 · Cited by 8 · see citing works
“68 Adaptive trials, including those that use RAR, require additional safeguards to ensure both the confidentiality of interim data and that interim analyses to inform trial adaptations and related decision-making processes do not introduce operational biases that could harm the credibility of trial…”
Self-citationCONSORT 2025 statement: updated guideline for reporting randomized trials: a Korean translation
Hopewell, S., Chan, A., Collins, P. G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · Ewha Medical Journal · doi:10.12771/emj.2025.00409 · Cited by 8 · see citing works
“아울러 주요 CONSORT 확장(유해성[ 24 ], 결과[ 25 ], 비약물학적 치료[ 27 ]) 및 기타 관련 보고 가이드라인( TIDieR [ 28 ]) 설계[ 33 ], 군집 시 험[ 34 ], 교차 시험[ 35 ], 초기 단계 시험[ 36 ], 요인 시험[ 37 ], 비열 등성 및 동등성 시험[ 38 ], 실용적 시험[ 39 ], 다군 시험[ 40 ], n - of - 1 시험[ 41 ], 시범 및 타당성 시험[ 42 ], 사람 내 무작위 배정 시험 [ 43 ]에 대한 권장사항이 포함된다.”
Self-citationAdaptive design trials in eating disorder research: A scoping review
Edney, L. C., & Pellizzer, M. L. (2024) · International Journal of Eating Disorders · doi:10.1002/eat.24198 · Cited by 7 · see citing works
Granholm, A., Munch, M. W., Meier, N. F., Sjövall, F., Helleberg, M., Hertz, F. B., Kaas‐Hansen, B. S., Thorsen‐Meyer, H., Andersen, L. W., Rasmussen, B. S., et al. (2024) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.14441 · Cited by 6 · see citing works
Flight, L., Brennan, A., Chick, S. E., Förster, M., Julious, S. A., & Tharmanathan, P. (2025) · BMC Medical Research Methodology · doi:10.1186/s12874-025-02566-6 · Cited by 4 · see citing works
Self-citationAdaptive clinical trials in surgery: A scoping review of methodological and reporting quality
Staibano, P., Oulousian, E., McKechnie, T., Thabane, A., Luo, S., Gupta, M. K., Zhang, H., Pasternak, J. D., Au, M., Parpia, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299494 · Cited by 4 · see citing works
Pyle, M., Loftus, L., Emsley, R., Freeman, D. H., Gillard, S., Gumley, A. I., Sierpatowska, J., Wood, L., O’Connor, R. C., Pfeiffer, P., et al. (2024) · Trials · doi:10.1186/s13063-024-08293-5 · Cited by 4 · see citing works
“In line with the Adaptive Designs CON-SORT Extension (ACE) statement [30], we report the unplanned changes in this protocol.”
ResultHosseini, R., Chen, Z., Goligher, E. C., Fan, E., Ferguson, N. D., Harhay, M. O., Sahetya, S. K., Urner, M., Yarnell, C. J., & Heath, A. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107560 · Cited by 4 · see citing works
Behal, M. L., Flannery, A. H., & Miano, T. A. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae134 · Cited by 4 · see citing works
Adaptive designs in dermatology clinical trials: Current status and future perspectives
Potvin, D., D’Angelo, P., Bennett, S., Jankićević, J., & Bissonnette, R. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20030 · Cited by 3 · see citing works
“32 The document provides insight on when it is particularly important to report any outcomes resulting from adaptive decisions.”
A landscape of methodology and implementation of adaptive designs in cancer clinical trials
Zhu, Y., Wang, W.-X., Cheuk, S.-K., Feng, G., Li, X.-G., Peng, J., Liu, Y., Yu, S.-R., Tang, J.-L., Chow, S.-C., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104402 · Cited by 3 · see citing works
Randomization in clinical trials with small sample sizes using group sequential designs
Bodden, D., Hilgers, R.-D., & König, F. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325333 · Cited by 3 · see citing works
“Adherence to the consolidated standards of reporting trials (CONSORT) guidelines, which call for transparent reporting of randomization and adaptive design features, is crucial to address these gaps [22,52].”
Confidence Intervals for Adaptive Trial Designs I: A Methodological Review
Robertson, D. S., Burnett, T. D., Choodari‐Oskooei, B., Dimairo, M., Grayling, M. J., Pallmann, P., & Jaki, T. (2025) · Statistics in Medicine · doi:10.1002/sim.70174 · Cited by 3 · see citing works
Self-citationConfidence Intervals for Adaptive Trial Designs II : Case Study and Practical Guidance
Robertson, D. S., Burnett, T. D., Choodari‐Oskooei, B., Dimairo, M., Grayling, M. J., Pallmann, P., & Jaki, T. (2025) · Statistics in Medicine · doi:10.1002/sim.70202 · Cited by 2 · see citing works
Self-citationPoonai, N., Arthur‐Hayward, V., Ali, S., Sabhaney, V. J., Doan, Q. H., Trottier, E. D., Gravel, J., Tran, N. A., Bhatt, M., Eltorki, M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0324515 · Cited by 2 · see citing works
“We will follow the CONSORT [35] (clinical trials) and ACE extension [36] (adaptive trials) guidelines for conduct and reporting.”
Cummings, J. L., Zhong, K., Ballard, C. G., Sano, M. C., & Mintzer, J. E. (2025) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2025.100107 · Cited by 2 · see citing works
Therapeutics in hospitalised adult patients with COVID-19
Roche, N., & Chalmers, J. D. (2024) · European Respiratory Society eBooks · doi:10.1183/2312508x.10020423 · Cited by 2 · see citing works
A maximum statistic for the one-sided location-scale alternative in the two-stage design
Murakami, H., & Neuhäuser, M. (2024) · Statistical Methods & Applications · doi:10.1007/s10260-024-00775-9 · Cited by 1 · see citing works
“Adaptive designs conduct a sequence of experiments and analyze the data from each stage separately, allowing for preplanned opportunities to modify the trial’s course based on accruing information, if necessary (Bauer and Köhne 1994; Pallmann et al. 2018; Dimairo et al. 2020).”
Thomas, M. J., Hughes, G., Cooke, K., Butler-Walley, S., Marshall, E., Bowyer, L., Wathall, S., Smith, J., Lawton, S., Brammar, J., et al. (2025) · NIHR Open Research · doi:10.3310/nihropenres.13930.1 · Cited by 1 · see citing works
Self-citationMahajan, M., Martín, L., Gaurav, K., & Suri, R. K. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127890 · Cited by 1 · see citing works
Adaptive designs were primarily used but inadequately reported in early phase drug trials
Wang, Y., Yao, M., Liu, J., Liu, Y., Ma, Y., Luo, X., Mei, F., Xiang, H., Zou, K., Li, L., et al. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02256-9 · Cited by 1 · see citing works
“…designs CONSORT Extension (ACE) statement, a reporting guidance for adaptive trials, was developed in 2020 to advise clinical researchers on how to report details of the adaptive design [18]; this statement is also considered a valid tool to evaluate the reporting quality of adaptive trials.”
Peng, Y., Lyu, P., & Peng, X. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.07.002 · Cited by 1 · see citing works
Smart, K. M., Abbott-Fleming, V., Birklein, F., Bruehl, S. P., Corcoran, E., Day, S. J., Ferraro, M. C., Grieve, S., Hilgers, R.-D., Ingram, C., et al. (2025) · PAIN Reports · doi:10.1097/pr9.0000000000001320 · Cited by 1 · see citing works
“22 We are not aware of any previous or ongoing CRPS trials using adaptive designs.”
Dawson, S. N., Chiu, Y., Earwaker, M., Klein, A. A., & Villar, S. S. (2022) · Research Square · doi:10.21203/rs.3.rs-1814203/v1 · Cited by 1 · see citing works
Brinquedo terapêutico reduz a ansiedade em procedimentos odontológicos? Estudo clínico randomizado
Carvalho, M. T. F., Pinheiro, S. L., de Sant’Anna, G. R., & Duarte, D. A. (2021) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e6248.2021
Optimal unplanned design modification in adaptive two‐stage trials
Pilz, M., Herrmann, C., Rauch, G., & Kieser, M. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2228
Factors affecting mortality, morbidity and survival in pylorus-preserving pancreaticoduodenectomy
(2022) · The Annals of Clinical and Analytical Medicine · doi:10.4328/acam.21238
Solovyeva, O., Dimairo, M., Weir, C. J., Hee, S. W., Ursino, M., Espinasse, A., Patel, D., Kightley, A., Hughes, S., Jaki, T., et al. (2023) · doi:10.31222/osf.io/jtpz2
Self-citationRandomized Trial of Fetal Surgery for Severe Left Diaphragmatic Hernia
Deprest, J. A., Nicolaides, K. H., Benachi, A., & Gratacós, E. (2023) · CRC Press eBooks · doi:10.1201/b23252-6
Staibano, P., McKechnie, T., Thabane, A., Olteanu, D., Nanji, K., Zhang, H., Lunny, C., Au, M., Gupta, M. K., Pasternak, J. D., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303315
“In 2020, CONSORT published an extension for adaptive trials to guide ACT reporting [13].”
Solovyeva, O., Dimairo, M., Weir, C. J., Hee, S. W., Espinasse, A., Ursino, M., Patel, D., Kightley, A., Hughes, S., Jaki, T., et al. (2023) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.76189
Self-citationLora, D., Blanco, A. L., de la Calle, G. M., Reyne, A. G., Ruiz‐Ruigómez, M., Sandubete, E. J. C., & Orenga, M. M. (2026) · Dialogues in Health · doi:10.1016/j.dialog.2026.100315
“Definitions of common ADCTs were derived from the literature [2,3,5,6,8,12] and are summarized in Table 1.”
Influential
- Authors
- Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., Nicholl, J. P., Coates, E., Biggs, K., Hamasaki, T., Proschan, M. A., Scott, J. A., Ando, Y., Hind, D., Altman, D. G., on behalf of the ACE Consensus Group, Dimairo, M., Hamasaki, T., Todd, S., Weir, C. J., Mander, A. P., Wason, J., Koenig, F., Julious, S. A., Hind, D., Nicholl, J., Altman, D. G., Meurer, W. J., Cates, C., Sydes, M., Jemiai, Y., Ashby, D., Yap, C., Waldron-Lynch, F., Roger, J., Marsh, J., Collignon, O., Lawrence, D. J., Bunce, C., Parke, T., Gazzard, G., Coates, E., Walton, M. K., Hopewell, S., Pallmann, P., Jaki, T., Biggs, K., Proschan, M. A., Scott, J. A., & Ando, Y.
- Affiliations
- University of Sheffield (GB)
- University of Edinburgh (GB)
- Newcastle University (GB)
- Cardiff University (GB)
- ORCID
- Venue
- Trials
- Published
- 2020-06-17
- Volume
- 21
- Issue
- 1
- Pages
- 528-528
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC7298968
- OpenAlex
- W3000741148
- Cited by
- 58
- References
- 278
- Citations by year
- 2026: 1 · 2025: 17 · 2024: 14 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 5
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Trials (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Cancer Research UK (16895)
- National Institute for Health and Care Research (DRF-2012-05-182, SRF-2015-08-001)
- Department of Health and Social Care
- University of Sheffield
- Medical Research Council (NIHR-SRF-2015-08-001, MR/L004933/1, MR/L004933/2, MR/N028171/1, MC_UU_12023/24, MR/L004933/1-R/N/P/B1)
- NIHR Academy (SRF-2015-08-001)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Social Sciences › Sociology and Political Science › Delphi Technique in Research
- Keywords
- adaptive design, CONSORT extension, reporting guidelines, randomised trials, research waste
- MeSH terms
- Delphi Technique, Humans, Periodicals as Topic, Publishing, Quality Control, Research Design, Reproducibility of Results, Randomized Controlled Trials as Topic, Guidelines as Topic, Consensus, Checklist
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
